Abstract
The preclinical ganglioside data hold great promise for these substances as potential therapy for a variety of neurologic conditions ranging from acute stroke and spinal cord injuries to chronic degenerative diseases. These data clearly indicate striking activity in both in vitro and in vivo models including the peripheral and central nervous systems. unlike quick-acting drugs such as insulin and antibiotics, time and patience are required to establish the clinical utility of this class of substances. The following is a brief historical overview describing the rationale behind the clinical program including a discussion of preliminary results.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
References
G. Pozza, V. Saibene, G. Comi, and N. Canal, The Effect of Ganglioside Administration in Human Diabetic Peripheral Neuropathy, in “Gangliosides in Neurological and Neuromuscular Function, Development and Repair,” M. M. Rapport, and A. Gorio, eds., Raven Press, New York, (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
DeFelice, S.L., Ellenberg, M. (1984). Gangliosides—Clinical Overview. In: Ledeen, R.W., Yu, R.K., Rapport, M.M., Suzuki, K. (eds) Ganglioside Structure, Function, and Biomedical Potential. Advances in Experimental Medicine and Biology, vol 174. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1200-0_53
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1200-0_53
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1202-4
Online ISBN: 978-1-4684-1200-0
eBook Packages: Springer Book Archive